Stockscreener 앱 받기
1,067.81
2.66%
26.52
Lilly Eli Co 주식(LLY)의 최신 뉴스
Eli Lilly: Buy Ahead Of Its Earnings Day (Preview) (NYSE:LLY) - Seeking Alpha
First-movers respond to biopharma herding into hot targets - Endpoints News
Rakuten Investment Management Inc. Makes New Investment in Eli Lilly and Company $LLY - MarketBeat
Migdal Insurance & Financial Holdings Ltd. Has $137.37 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Joel Isaacson & Co. LLC Acquires 3,976 Shares of Eli Lilly and Company $LLY - MarketBeat
Recludix Tackling Inflammatory Diseases with Backing From Eli Lilly - sdbj.com
Middleton & Co. Inc. MA Has $9.24 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Dynasty Wealth Management LLC Sells 3,206 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Faces Regulatory Delay as Key Drug Approval Pushed to 2026 - AD HOC NEWS
What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026? - The Motley Fool
Abivax CEO Dismisses Rumors of Eli Lilly (LLY) Takeover as ‘Noise’ - TipRanks
Eli Lilly (LLY) Denies Acquisition Talks with Abivax (ABVX) - GuruFocus
Bernstein reiterates Outperform rating on Eli Lilly stock with $1,300 price target - Investing.com
New GCGR agonists disclosed in Eli Lilly patent - BioWorld MedTech
Abivax CEO dismisses 'noise' around rumored Eli Lilly bid - Reuters
Guggenheim Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,161 - 富途资讯
Eli Lilly (LLY) Receives FDA Breakthrough Designation for New Ca - GuruFocus
Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer - Eli Lilly
FDA grants Breakthrough status to drug for hard-to-treat ovarian cancer - Stock Titan
Abivax CEO dismisses ’noise’ around rumored Eli Lilly bid By Reuters - Investing.com
Morgan Stanley reiterates Overweight rating on Eli Lilly stock ahead of obesity trial data By Investing.com - Investing.com South Africa
Morgan Stanley reiterates Overweight rating on Eli Lilly stock ahead of obesity trial data - Investing.com
Eli Lilly (LLY) Faces Competition from Structure Therapeutics' P - GuruFocus
Eli Lilly Faces Headwinds Amid Regulatory Delay and Legal Challenge - AD HOC NEWS
Silicon Meets Science: NVIDIA and Eli Lilly Launch $1 Billion AI Lab to Engineer the Future of Medicine - FinancialContent
The Best Healthcare Stocks to Buy With $5,000 in 2026 and Hold Forever - Finviz
Compounder sues Lilly and Novo for suppressing GLP-1RA competition - Pharmaceutical Technology
Eli Lilly's Taltz and Zepbound Combo Delivers Superior Results in Landmark Psoriatic Arthritis Trial - Finviz
Eli Lilly price tries to recoup some lossesForecast today19-01-2026 - Economies.com
Eli Lilly's (NYSE:LLY) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth - 富途资讯
Eli Lilly vs. Novo Nordisk: Which Stock Offers More Upside? - CoinCentral
OpenAI Backed Chai Discovery Partners With Eli Lilly to Accelerate Biologics Discovery - AIM Media House
Chai Discovery Strikes Eli Lilly AI Drug Deal - findarticles.com
Eli Lilly's Weight Loss Portfolio Generates $10 Billion in Quarterly Revenue - Intellectia AI
Prediction: 2026 Will Be the Year of Eli Lilly - The Motley Fool
Eli Lilly Faces Regulatory Delay for Weight-Loss Drug Candidate - AD HOC NEWS
What Eli Lilly (LLY)'s NVIDIA AI Lab And Obesity Data Reveal About Its Obesity Leadership Narrative - Yahoo Finance
The Truth About Eli Lilly (NYSEreplacing with LPLA): Why Everyone Is Suddenly Watching This Stock - AD HOC NEWS
Notable healthcare headlines for the week: Eli Lilly, UnitedHealth, and Boston Scientific in focus - MSN
Could Acquiring Ventyx Biosciences Send Eli Lilly Stock Soaring in 2026? - The Motley Fool
Eli Lilly Shares Face Pressure Following Regulatory Setback - AD HOC NEWS
Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week - TechStock²
This pharmaceutical executive has Trump's ear - Politico
BMO Reaffirms Eli Lilly and Company (LLY) as an Obesity Market Leader - Finviz
Eli Lilly’s Strategic Moves in the Weight-Loss Drug Arena - AD HOC NEWS
Eli Lilly Partners with Nvidia to Invest $1 Billion in AI Drug Discovery - Intellectia AI
Eli Lilly: A Strong Player in the Pharmaceutical Arena - The Motley Fool
Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang - TechStock²
Stock Quote & Chart | Eli Lilly and Company - Eli Lilly
Chai Discovery and Eli Lilly Partner to Accelerate AI-Driven Drug Development - Букви
From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug development - TechCrunch
Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy? - The Motley Fool
Novo's Wegovy pill makes encouraging start in weight-loss race vs Lilly - Reuters
LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling - Yahoo Finance
Nvidia and Eli Lilly Are Partnering on a $1 Billion Lab. Here's What Investors Need to Know. - Finviz
NVIDIA and Lilly launch $1B AI lab for drug discovery ... - eeNews Europe
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,265 - 富途资讯
Rakuten Securities Inc. Boosts Stock Position in Eli Lilly and Company $LLY - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Has $15.61 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
NVIDIA and Eli Lilly Launch AI Co-Innovation Lab for Drug Development - HLTH
Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed - TechStock²
Forbes J M & Co. LLP Acquires 3,186 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Holdings Reduced by Fjarde AP Fonden Fourth Swedish National Pension Fund - MarketBeat
Blalock Williams LLC Buys New Position in Eli Lilly and Company $LLY - MarketBeat
[JPM 2026] ABL Bio seeks next license-out after GSK, Eli Lilly deals - theinvestor.co.kr
Regulatory Hurdles and Legal Challenge Weigh on Eli Lilly Shares - AD HOC NEWS
Eli Lilly stock slides after FDA pushes obesity pill decision to April 10 - TechStock²
Lobbying Update: $2,200,000 of ELI LILLY AND COMPANY lobbying was just disclosed - Quiver Quantitative
IU and Eli Lilly team up to study impact of GLP-1 drugs in workplace - WRTV
1.43%
0.57%
자본화:
|
볼륨(24시간):